EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting Bcl-xL with Navitoclax Effectively Eliminates Senescent Tumor Cells That Appear Following CEP-1347-Induced Differentiation of Glioma Stem Cells

Senri Takenouchi, Yasufumi Ito, Kazuki Nakamura, Yurika Nakagawa-Saito iD, Yuta Mitobe, Keita Togashi, Shuhei Suzuki iD, Asuka Sugai, Yukihiko Sonoda iD, Chifumi Kitanaka, Masashi Okada iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26146984 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Senri Takenouchi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan. Hauptthemen laut MEDLINE: Aniline Compounds, Neoplastic Stem Cells, Cellular Senescence, bcl-X Protein. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cellular senescence is a state of the durable cell cycle arrest of dysfunctional cells, which has been associated with the promotion of tumor cell reprogramming into a stem cell state. We previously reported that the mixed lineage kinase (MLK) inhibitor CEP-1347 promotes the differentiation of glioma stem cells (GSCs)—key contributors to glioblastoma recurrence and therapy resistance—into non-stem tumor cells. However, we also noted that CEP-1347–treated GSCs exhibited a morphological change suggestive of senescence. Therefore, we herein investigated whether CEP-1347 induces senescence in GSCs and, consequently, if senescent GSCs may be eliminated using senolytics. Cell death induced by CEP-1347 in combination with senolytic agents or with the knockdown of anti-apoptotic BCL2 family genes, as well as the effects of CEP-1347 on the expression of senescence markers and anti-apoptotic Bcl-2 family proteins, were examined. The results obtained showed that CEP-1347 induced senescence in GSCs accompanied by the increased expression of Bcl-xL. Among the panel of senolytic agents tested, navitoclax, a BH3 mimetic, efficiently induced cell death in GSCs when combined with CEP-1347 at concentrations clinically achievable in the brain. The knockdown of Bcl-xL resulted in more pronounced GSC death in combination with CEP-1347 than that of Bcl-2. These results suggest that combining CEP-1347 with the targeting of Bcl-xL, the expression of which increases with CEP-1347-induced senescence, is a rational approach to ensure the elimination of GSCs, thereby improving the outcomes of glioblastoma treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aniline CompoundsNeoplastic Stem CellsCellular Senescencebcl-X ProteinSulfonamidesGliomaCell DifferentiationHumansCell Line, TumorApoptosisAntineoplastic Agents

Stichwörter der Autor:innen

drug repositioningglioblastoma multiformestem cell capacitytumor-initiating cells

Substanzen

navitoclaxAniline Compoundsbcl-X ProteinSulfonamidesBCL2L1 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan.
  • Department of Obstetrics and Gynecology, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan.
  • Department of Neurosurgery, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan.
  • Department of Ophthalmology and Visual Sciences, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan.
  • Department of Clinical Oncology, Yamagata Prefectural Shinjo Hospital, 720-1 Kanazawa, Shinjo 996-8585, Japan.
  • Research Institute for Promotion of Medical Sciences, Yamagata University Faculty of Medicine, Yamagata 990-9585, Japan.

ORCID-Profile: Yurika Nakagawa-Saito, Shuhei Suzuki, Yukihiko Sonoda, Masashi Okada

Förderung

  • Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan

Zitieren

APA

Takenouchi, S., Ito, Y., Nakamura, K., Nakagawa-Saito, Y., Mitobe, Y., Togashi, K., Suzuki, S., Sugai, A., Sonoda, Y., Kitanaka, C., & Okada, M. (2025). Targeting Bcl-xL with Navitoclax Effectively Eliminates Senescent Tumor Cells That Appear Following CEP-1347-Induced Differentiation of Glioma Stem Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26146984

Vancouver

Takenouchi S, Ito Y, Nakamura K, Nakagawa-Saito Y, Mitobe Y, Togashi K, et al. Targeting Bcl-xL with Navitoclax Effectively Eliminates Senescent Tumor Cells That Appear Following CEP-1347-Induced Differentiation of Glioma Stem Cells. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26146984

BibTeX
@article{Takenouchi2025,
  author = {Takenouchi, Senri and Ito, Yasufumi and Nakamura, Kazuki and Nakagawa-Saito, Yurika and Mitobe, Yuta and Togashi, Keita and Suzuki, Shuhei and Sugai, Asuka and Sonoda, Yukihiko and Kitanaka, Chifumi and Okada, Masashi},
  title = {Targeting Bcl-xL with Navitoclax Effectively Eliminates Senescent Tumor Cells That Appear Following CEP-1347-Induced Differentiation of Glioma Stem Cells},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26146984}
}
Kostenlos starten →